ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Prime Minister Narendra Modi is counting on a two-pronged stimulus of tax and interest rate cuts to turn around India’s ...

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

Better access and capability scores were associated with integrated practice ownership and participation in accountable care ...

Researchers have used mathematical analysis tools to study the effect of classical music on a fetal heartbeat and identify patterns in heart rate variability. They recruited 36 pregnant women and ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...